New England Journal of Medicine· 2017Q1

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

Scott Antonia, Augusto Villegas, Davey B. Daniel, David Vicente et al.

4,566citations
Q1SCImago
2017year

Short summary

Consolidation therapy with durvalumab after chemoradiotherapy significantly extended progression-free survival (PFS) by over 11 months (16.8 vs. 5.6 months) in patients with unresectable stage III non-small-cell lung cancer (NSCLC).

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Oncology

OncologyMedicine